Improving detection of immune-related side effects in cancer patients
Official title: Informatics strategies to improve immune-related adverse event detection in cancer patients
Funded at Brigham and Women's Hospital · NIH-10979489 · Data updated 2026-11-12
This study is looking to make it easier to spot side effects that can happen to cancer patients using new immune treatments, so if you join, your health records will help us learn how to better track and understand these issues for better care.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brigham and Women's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | September 1, 2024 |
| Project end | August 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $459,867 |
| NIH project number | 1R01CA294033-01 |
| Project ID | NIH-10979489 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are cancer patients who have been treated with immune checkpoint inhibitors and may experience immune-related adverse events.
✕Less likely to help
Patients who have not received immune checkpoint inhibitors or do not experience immune-related adverse events may not benefit from this research.
What this research studies
This research focuses on enhancing the detection of immune-related adverse events (irAEs) that can occur in cancer patients treated with immune checkpoint inhibitors. By utilizing advanced informatics technologies, particularly natural language processing, the project aims to automatically identify and monitor these side effects from electronic health records (EHR). The goal is to improve the understanding of irAE rates and severity, ultimately leading to better clinical care and patient outcomes. Patients participating in this research may contribute to a clinical trial that assesses the effectiveness of these automated detection methods.
Why it matters
Potential benefit: If successful, this research could lead to improved identification and management of immune-related side effects, enhancing the quality of life for cancer patients.
How similar studies have gone: Other research has shown promise in using informatics and natural language processing for adverse event detection, indicating that this approach could be effective.
Where this research is happening
-
Brigham and Women's Hospital
Boston, United States Active
Researchers
- Principal investigator: Bitterman, Danielle S — Brigham and Women's Hospital
- Study coordinator: Bitterman, Danielle S
Related research
Other NIH-funded projects on the same topics.
-
Informatics tools to better detect immune-related side effects in cancer patients
A new informatics approach using smart language models will help doctors identify and track immune-related side effects from cancer immunotherapy in electronic health records, aiming to improve patient care.
-
AI to detect immune-related side effects after cancer immunotherapy
This project uses AI language models to find and flag immune-related side effects in medical records of people treated with immune checkpoint inhibitor cancer therapies.
-
Mycophenolate mofetil with prednisone for immune-related hepatitis from cancer therapy
This study tests whether starting mycophenolate mofetil plus prednisone can help liver inflammation caused by immune checkpoint inhibitors in adults with moderate to severe immune-related hepatitis.
-
Thymosin Alpha-1 plus PD-1 therapy in older adults with advanced melanoma
This trial tests whether adding Thymosin Alpha-1 to a PD-1 antibody helps people age 60 and up with advanced melanoma.
-
Inhaled budesonide to prevent recurrent checkpoint inhibitor–related pneumonitis
This study tests whether adding inhaled budesonide to usual care can prevent recurrence of pneumonitis in adults who developed grade 2 or higher lung inflammation from checkpoint inhibitor immunotherapy.
-
Investigating serum ferritin as a biomarker for immune-related adverse events
This study is testing if a blood marker called serum ferritin can help doctors identify and predict immune-related side effects in patients with cancer receiving different types of treatment.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.